UW researchers discover AI-powered breakthrough that could boost precision cancer treatment
A breakthrough in the science used to customize the treatment of cancer and other diseases is so promising that researchers at the University of Washington are planning to launch a company to commercialize the technology.
The strategy uses artificial intelligence to create proteins that recognize and bind to specific markers on diseased cells, creating what are essentially biological neon signs that attract immune cells to destroy the targets.
The research comes from the lab of Nobel laureate David Baker and UW Medicine's Institute for Protein Design, which Baker leads, and is being published today in the journal Science. Additional study authors come from multiple UW departments, the Garcia Lab at Stanford University, and the Scheinberg Lab at Memorial Sloan Kettering Cancer Center.
'Detecting unhealthy cells is one of the main jobs of the immune system, but it doesn't always notice the subtle signs of cancer or viral infection,' Baker said in a statement. 'In this study, we show that computer-designed proteins can help human immune cells spot the right targets and function more effectively.'
The work could lead to significant advancements in precision immunotherapy, which delivers disease-fighting drugs that are crafted for individual patients. The key to this personalized approach lies in understanding how cells display their identity on their surfaces.
The outside membrane of a cell is studded with molecules that include small proteins called peptides that reveal a cell's inner workings, including if it's cancerous or infected by a virus such as HIV. The scientists used RFdiffusion and ProteinMPNN — AI-tools built by the Institute for Protein Design — to efficiently and cheaply engineer proteins that recognize the unique peptides.
University of Washington biochemist and Nobel Prize laureate David Baker at his office in Seattle. (GeekWire Photo / Lisa Stiffler)
The custom-made proteins can then be integrated into chimeric antigen receptors (CARs), which are engineered molecules that attract and activate immune-system warriors called T cells to attack specific targets.
In their study, the researchers designed proteins for 11 peptide targets and eight successfully triggered a T-cell response. Of those eight, two produced such a strong immune response that the T cells killed the targeted cells.
The peptide targets included HIV fragments and tumor-related protein mutations.
'We've shown how advances in protein design could make personalized cancer therapy possible, and we intend to start a company to turn these results into real therapies that benefit patients,' said Bingxu Liu, co-lead author of the study and postdoctoral scholar in the Baker Lab.
Since 2014, the Institute for Protein Design has spun off 10 startups, and Baker has co-founded 21 tech companies. When Baker won the Nobel Prize in October, the Royal Swedish Academy of Sciences noted that 'his research group has produced one imaginative protein creation after another, including proteins that can be used as pharmaceuticals, vaccines, nanomaterials and tiny sensors.'
The researchers involved in the latest study explained that the strategy can be easily adapted to new scenarios. Within days, the team was able to take one of its successful proteins and use AI to modify it to target new cancer and virus-associated peptides.
The process could make it much cheaper to create personalized treatments.
'I'm hopeful that this will lead to new therapies that are more accessible to patients around the world who do not benefit from current state-of-the-art cancer treatments,' said Julia Bonzanini, a co-lead author and Baker Lab graduate student.
Researchers worldwide can access online the open-source software used in the research.
Other authors of the Science paper, titled 'Design of high-specificity binders for peptide–MHC-I complexes,' are Nathan Greenwood, Amir Motmaen, Jeremy Meyerberg, Tao Dao, Xinyu Xiang, Russell Ault, Jazmin Sharp, Chunyu Wang, Gian Marco Visani, Dionne Vafeados, Nicole Roullier, Armita Nourmohammad, David Scheinberg and Christopher Garcia.
RELATED:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
24 minutes ago
- Forbes
The Future Of Skin Protection, Sunscreens And Cosmetics with SPF
As science and skincare come together, sun protection products have become part of our everyday health and beauty routine. The industry is growing, and according to Grand View Research, the global sun care cosmetics market size was estimated at USD 10,191.7 million in 2024 and is projected to reach USD 19,514.2 million by 2033, growing at a CAGR of 7.3% from 2025 to 2033. Rising concerns about the detrimental effects of sunrays and improved awareness regarding skin cancer are the major factors driving the market growth and innovation. What was once a daily application before spending the day on the beach is evolving into an all-year-round skincare category that is multi-functional and targets hydration, anti-ageing, and makeup. Consequently, these changing consumer habits are reshaping a very competitive landscape for beauty and dermatology brands. The Importance Of SPF: Why SPF Is Non-Negotiable Celebrity Cosmetic Dermatologist, Dr Simon Ourian, tells me that wearing sunscreen is one of the best ways to protect your skin's youthful look as it helps delay the appearance of aging signs like dark spots, dehydration, and sagginess. 'A SPF in your morning routine is non-negotiable for me. I believe that healthy skin is beautiful skin,' he says over Zoom. Hydration is also key, as explained by Dr Uliana Gout, who tells me over email that all too often we reach out for a cocktail in the sun, followed by espresso shots, and the pattern goes on as we party in the sun. Skin becomes dehydrated and dull, whilst fine lines take hold and pores dilate. She explains to me that a simple remedy is to drink 2 liters of water or juices (ideally the green ones) daily, as the basis of essential skin hydration and glow. Understanding SPF Ratings. What Do They Really Mean? There is often confusion over SPF ratings, which can lead to misplaced consumer confidence. Dr. Dev Patel, founder of CellDerma, suggests over email, that we should always choose broad-spectrum protection, a type of sunscreen that will guard you against both UVA (UVA rays permeate deeper into the skin, contributing to premature ageing, wrinkles, and long-term DNA damage) and UVB rays (UVB rays cause sunburn and redness, damaging the outer layers of the skin). SPF ratings are often misunderstood. Patel tells me that SPF 25 blocks about 96% of UVB rays; SPF 30 about 96–97%; SPF 50 about 98%. 'In reality, once you exceed SPF 15 (which blocks 93%), the incremental increase in UVB protection becomes minimal,' he says Patel is also an advocate of mineral-based sunscreens, which physically block rays rather than absorb them. Some consumers avoid them due to a common misconception that they leave a white cast behind, but advances in formulation are making these products lighter, more transparent, and suitable for everyday wear. 'What truly matters more is how frequently the product is applied, how it performs on skin, and the quality and breadth of the protection provided,' he Formulations: One-Step, Multiple Benefits As customers expect more from their skincare and seek products that address multiple concerns, we are witnessing a rise in multi-tasking offerings that blend sun protection with hydration, anti-aging, and even vitamin D optimization. HELIOCARE 360° Advanced Gel Body SPF50+, for example, is a body sunscreen that prevents and repairs sun damage and enhances the functionality of vitamin D in the skin. The fast-absorbing formula is also resistant to water and safe for children aged 2 years and above. Dubbed the 'everything day cream', the Skin Diary's Age Defence Moisturizing Day Cream is another multi-tasker that protects your skin from the sun and against cellular ageing. Co-founded by Dr Clare Kiely, Professor Chris Griffiths, Dr Tamara Griffiths and Dr Richard Barlow in 2023, the range provides statistically significant protection against UV-induced epigenetic activity, restoring youthful skin function by helping prevent cellular senescence, inflammation and the breakdown of collagen and fibrillin. This multifunctional approach aligns with recent consumer demands, as it translates into products that deliver with fewer steps. Bondi Sands' Sunny range follows the same principle, integrating UVA/UVB defense, hydration, and anti-aging into lightweight formulations. All the products in their sun care range also feature Vitamin E and Australian Hibiscus to nurture the skin and keep it hydrated while protected from the sun. All are broad-spectrum, providing both UVA and UVB protection. The Sunny products have been developed for everyday use and include an SPF 50 Face Serum, an SPF Face Lotion and an SPF 50 Face Mist, which combine UV protection with anti-ageing, hydration, and even blue light defense. A further example of a sunscreen with added benefits is the fashion-collaboration product Narcyss x Chimi SPF 50+, which blends sun care with luxury skincare aesthetics in a formula that helps promote a more even and radiant complexion while fortifying the skin's natural SPF Products: Where Protection Meets Cosmetics Tinted sunscreens are bridging the gap between beauty and sun care, offering coverage in numerous shades, skincare benefits, and high SPF in one product. Ultra-light, invisible sunscreens with universal tinting are amongst some of the most effective innovative products in the sector, catering to all skin tones and types without compromising on sun protection. Naked Sundays' innovative formulas, for instance, incorporate Australian sunscreen innovation to create effective skincare and makeup-based SPF. The range includes bronzing drops, serums, lip oils and mist-like sprays. Their philosophy focuses on 'topping up' your SPF, as sunscreens only last 60 minutes when you are outdoors. Founder Samantha Brett emphasizes layering SPF over makeup, with formulas like their Beauty Screen Mineral Tints providing SPF50 protection in a sheer, wearable finish. She tells me over email that by putting makeup, sun-care and skincare in one easy-to-use product, her morning routine takes a few minutes, while she gets the same high-quality makeup look, with a bonus of SPF50. 'At Naked Sundays," she says, 'we emphasize layering and reapplying SPF throughout the day, even over makeup. However, our SPF50 Beauty Screen Mineral Tints are SPF50, and they're sheer enough so you can actually wear the full amount without looking too cakey; but if you don't like a full coverage, it's best to layer your SPF'. Merit is another global beauty player entering this category. This year, they launched The Uniform Tinted Mineral SPF 50, their first-ever SPF product. The plant-based mineral SPF is designed for everyday wear and is available in 15 shades, from light to medium, offering sheer, buildable coverage with a natural, skin-like finish. Unlike chemical sunscreens, which absorb UV rays and convert them into heat, The Uniform is a mineral sunscreen that reflects UV rays, forming a protective barrier against potential skin damage. AllSkin Med's Mineral Fluid SPF 50, available in beige and bronze, brings dermatologist-grade protection to tinted formats. This high-level, broad-spectrum protection against daylight (UV, visible light and infrared-A) is combined with natural-looking foundation coverage using 100% mineral filters. In addition, for a universally tinted sunscreen, PCA Skin offers a water-resistant SPF 45 formula (lasting 80 minutes) that provides sheer protection with an antioxidant boost. It can be used alone or layered under makeup. Self-Tanning: A Strong Alternative As sun safety awareness grows, we are seeing a rise in self-tanning products being positioned as viable alternatives to direct sun exposure. Sienna's Gradual Organic Self-Tan Rose Mist is a gentle facial mist that provides a natural-looking, buildable glow. Infused with Rose Water, Hyaluronic Acid, and Niacinamide, this product hydrates while bronzing and is suitable for use on sensitive skin. For a different application method, Dr Dennis Gross' Alpha Beta Glow Pads for Face & Body are an all-in-one self-tanning pad that delivers a natural-looking tan in just two hours, with zero sun exposure and no UV risk. The pads exfoliate and brighten from the first application, and are infused with Vitamin E and Phospholipids. The quick-drying tan fades naturally over the course of a week—or can be reapplied 2–3 times a week for a buildable, long-lasting glow. If you are looking for a serum that delivers light coverage, ILIA's Super Serum Skin Tint, SPF 30, simplifies your routine by combining your makeup, skincare, and SPF into one simple step. The light formula is available in 17 different shades. These products cater to consumers who are committed to tanning but wish to avoid UV exposure Care And Sun Protection An area that is often overlooked, the lips, is now becoming more prominent. As part of their sun shield range, for instance, Paul & Joe offers a luxurious Protecting Lipstick Refill & Case, a moisturizing lipstick with built-in SPF, infused with jojoba oil, cationic hyaluronic acid, and 'happy clover' for protected lips. Rehab also provides an SPF 15 Lip Oil that is non-sticky and peach-tinted, delivering high-shine and hydration. The glossy formula enhances your natural lip color while providing SPF 15 protection for everyday wear. This trend aligns with customers who are looking for complete sun protection. Smart SPF: UV Detection Patches The latest technology and innovation provide a visual cue to remind you when it's time to apply sunscreen. Sun Patches in the form of stickers serve as a reminder for reapplying sun protection, ensuring you shield your skin from harmful UV rays. The pads change color to indicate when reapplication is needed. Engineered for controlled release of ingredients through the skin, the transdermal patches are specifically formulated to penetrate this barrier but gradually release the ingredients over a predetermined period. Ingredients include Hydrocolloid, which forms a protective barrier shielding the area from external factors like dirt and moisture, and UV Powder, which is embedded in the patch. This allows the patch to react to UV exposure and change color, indicating when to use Protection From The Sun Hair care brands are also incorporating UV defense into repair and styling products: summer can be harsh on your hair but using the correct products can prevent it from getting damaged. Fudge Professional's Bond Builder Repair Shampoo and Conditioner, for example, restore the entire hair. As their brand ambassador, Jonathan Andrew, explains, 'split ends don't just stop at the tip. It's like pulling a piece of string apart—it keeps splitting up the shaft, leaving your hair thinner and more damaged. That's why regular trims help, but between cuts, you need the right repair system.' There are also sprays that can be applied to protect the hair in the sunshine, including K18's Heatbounce, a conditioning heat protector devised for guarding from the heat of styling tools as well as from the sunshine; Hairburst, a multi-tasking, lightweight elixir that thickens, lifts, and looks after while stimulating hair growth at the root without weighing hair down (it also shields the hair from heat styling and environmental aggressors); and Bjorn Axen's Heat Styling Protection, a heat and UV spray that nourishes the hair while ensuring protection. For humid climates, the OSMO Guardian Angel is a great solution that will reduce frizz whilst protecting your hair by ensuring it maintains optimum hydration. This concern is also addressed by Rehab, which has just launched its Sunshine Spritz collection with an advanced formula that hydrates and nourishes while shielding strands from UV exposure and frizz-inducing humidity. The range is scented with their tropical Sunshine Spritz fragrance –a blend of magnolia, coconut, sandalwood, and sea salt. Post-Sun Recovery: Repair And Rejuvenation Looking after your skin after it has been exposed to the sun is as essential as preventing sun damage. Facialist and founder of Fab Skincare and Fab Salons, Laura Porter, tells me over email that after a period of sun exposure, there are some steps that we should take to ensure optimum skin. To boost radiance, she suggests prioritizing a gentle but deep double cleanse routine to rebalance the skin, massaging the skin to stimulate lymphatic drainage, using polyhydroxy acids (PHAs) instead of AHAs, as they exfoliate and hydrate in one step, applying a barrier repair serum nightly to restore the skin's essential lipids, and using vitamin C products which brighten and support collagen production. This is also confirmed by Dr Gout, who advises that upon returning home, we get onto our retinoids, antioxidants, exfoliants and depigmenters within a week or so. 'But please get a consultation so the ingredients, percentages, and pH are all tailored to you and your needs!' says Dr Gout. 'We always see our clients post summer holidays to reset their skincare routine for the next season: Autumn,' she says. The Future Of SPF As sun protection moves from being a seasonal product to becoming part of our daily routine, we are witnessing a growing industry driven by consumer demands. From alternatives to traditional foundations to detection patches, the sun care category is repositioning itself in the marketplace, reflecting our changing beauty and health concerns.
Time Business News
32 minutes ago
- Time Business News
Next-Gen Breakthroughs Reshaping the In Vitro Diagnostics
In vitro diagnostics (IVD) refers to tests on blood, tissue, or other samples taken from the human body to detect diseases, conditions, or infections. These tests are usually used in laboratories or at the point of care for diagnosis, monitoring and treatment guidance. IVD market has increased due to increased chronic and infectious diseases, increasing demand for early and accurate diagnosis, progress in clinical technologies (eg molecular diagnosis and AI-operated equipment), expansion of elderly population, and globally more healthcare awareness. Key Growth Drivers and Opportunities Increased Chronic and Infectious Diseases: An increase in chronic and infectious diseases increases in vitro diagnostics (IVD) market, as these conditions require initial, accurate and continuous testing for effective treatment and management. Chronic diseases such as diabetes, cancer, and heart disease demand regular monitoring through blood tests, biomarkers and genetic screening, while infectious diseases such as Covid -19, HIV and tuberculosis increase the need for rapid and large -scale clinical solutions. This increased disease burden increases the demand for advanced IVD tools, which is motivated to adopt health care systems more efficient, automatic and accurate clinical technologies to improve the results of the patient. Challenges In vitro diagnostics (IVD) market faces several borders, including high costs, regulatory complications, and reimbursement challenges of advanced clinical technologies that obstruct market access. Limited infrastructure and skilled workers also prohibit adoption in low- and moderate-income countries. Additionally, concerns over the accuracy and standardization of some rapid or point-key-care tests can affect confidence in reliability and results, slowing out extensive implementation. Innovation and Expansion Launch of a New HealthTech Hub to Promote In Vitro Diagnostics In March 2025, Industry, academia, and the healthcare sector convened at the NIHR HealthTech Research Centre in In Vitro Diagnostics (HRC IVD) opening event to deliberate on the Center's goals and priorities. The HRC IVD, which is hosted by Imperial College London and Imperial College Healthcare NHS Trust and funded by the National Institute for Health and Care Research (NIHR), will aid in the advancement and uptake of diagnostics. The HRC IVD provides experience in regulatory clearances, real-world evidence creation, health economics, and overcoming adoption hurdles, with a focus on cancer, infectious and respiratory illnesses, critical care, and primary and social care. MP Biomedicals Releases Next-Generation GI Disease Diagnostic Kits In August 2024, MP Biomedicals has added new qualitative fast tests based on immunochromatography to their suite of in vitro diagnostic assays for infectious disorders. The new diagnostic kits from MP Biomedicals use state-of-the-art technology to provide reliable findings, allowing medical practitioners to quickly and accurately detect Vibrio cholerae serogroups O1 and O139, Salmonella typhi, and Helicobacter pylori. These cutting-edge diagnostic technologies have the potential to completely transform the field of gastrointestinal health diagnostics by giving medical practitioners dependable instruments for enhanced patient outcomes and early identification with previously unheard-of precision. These kits provide doctors, lab workers, and researchers useful tools that may be used in both clinical and research contexts. Inventive Sparks, Expanding Markets The key players operating the in vitro diagnostics market includes, Abbott, Qiagen, Agilent Technologies Inc., bioMerieux SA, Siemens Healthineers, Sysmex Corp., Danaher Corporation, F-Hoffman-La Roche Ltd., Charles River Laboratories, Becton Dickinson and Company, and Others. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Yahoo
an hour ago
- Yahoo
Infectious Disease Therapies Market Projected to Reach $101 Billion by End of 2030
"As infectious diseases like HIV, hepatitis, tuberculosis, and influenza continue to challenge global health systems, new breakthroughs such as long acting injectables and monoclonal antibodies are driving better patient outcomes and fueling market growth, especially in the face of rising drug resistance." BOSTON, Aug. 14, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Global Markets for Infectious Disease Treatments" is expected to grow from $72.5 billion in 2025 to $101 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.9% during the forecast period of 2025 to 2030. This report analyzes the global market for infectious disease therapeutics, vaccines, and diagnostics, covering diseases such as HIV, influenza, hepatitis B and C, RSV, TB, HSV, malaria, rotavirus, and viral hemorrhagic fevers. It highlights market trends, challenges, and opportunities, along with insights into new products, acquisitions, collaborations, and ESG developments. The report also ranks leading companies by market share and provides detailed profiles of them. Excluded from the report are vector control strategies, symptomatic treatments, generic suppliers, and certain hospital-based diagnostic methods. This report is particularly relevant today because the COVID-19 pandemic has reshaped global priorities around infectious diseases. It exposed critical gaps in healthcare systems and underscored the urgent need for rapid diagnostics, effective treatments, and scalable vaccine platforms. In response, governments, organizations, and private companies invested in infectious disease research and infrastructure, driving innovation and global collaboration. The pandemic also highlighted the importance of early detection, surveillance, and preparedness, leading to renewed attention on emerging and neglected infectious diseases. The factors driving the market's growth include: Increasing Resistance to Drugs: Drug resistance is rising as bacteria and viruses evolve to withstand existing treatments, making infections harder to cure. This pushes pharmaceutical companies to develop new drugs and therapies, driving growth in the infectious disease treatment market. Global Efforts to Combat Infectious Diseases: Governments and international organizations are investing in public health initiatives, research, and vaccination programs to control infectious diseases. These efforts create strong support for treatment development and expand market opportunities worldwide. Technological Advances in Diagnostics and Therapeutics: Innovations like rapid testing, AI-based drug discovery, and advanced vaccines are improving how diseases are detected and treated. These technologies enhance efficiency and effectiveness, boosting demand for more effective diagnostic and therapeutic solutions. Climate Change: Changing climate patterns are expanding the reach of disease-carrying organisms, leading to the spread of infections in new regions. This increases the need for treatments in previously unaffected areas, stimulating market expansion and adaptation. Request a sample copy of the global market for infectious disease treatments report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $68.3 billion Market size forecast $101 billion Growth rate CAGR of 6.9% for the forecast period of 2025-2030 Segments covered Product, Disease, and Region Regions covered North America, Europe, Asia-Pacific, Middle East and Africa, and South America Countries covered U.S., Canada, Mexico, U.K., Germany, France, China, India, and Japan Market drivers • Increasing resistance to drugs. • Global efforts to combat infectious diseases. • Technological advances in diagnostics and therapeutics. • Climate change. • Increase in international travel. Interesting facts: More than 85% of hepatitis B virus infections never receive a diagnosis. Due to climate change, mosquito-borne infectious diseases are on the rise. The worldwide incidence of dengue has risen eightfold in the past 20 years. Emerging startups: Codagenix: The company develops vaccines and viral therapeutic candidates for infectious diseases. Its intranasal vaccine candidate, CoviLiv, is a live-attenuated vaccine against COVID-19. nChroma Bio: A biotechnology company advancing genetic medicines. CRMA-1001 is an epigenetic editor in development as a potential treatment for chronic hepatitis B and hepatitis D. The company plans to submit a clinical trial application in 2025. The report addresses the following questions: What are the projected size and growth rate of the Infectious disease treatments market?- The global Infectious disease treatments market was estimated at $68.3 billion in 2024. The market is projected to reach $101 billion in 2030, growing at a CAGR of 6.9% during the forecast period. Which market segments are covered in the report?- The report includes historical data and market projection on sales by product type, disease, and region. Which product type segment will be dominant through 2030?- Therapeutics is expected to have the largest share of the product type segment through the end of 2030. Which product type is showing the fastest growth?- The vaccine segment is the fastest growing product type segment. What are the key challenges and opportunities in the market?- Challenges: Pricing pressure is a significant factor restraining the growth of the infectious disease treatment market, particularly in low and middle-income countries where healthcare budgets are limited. Lack of awareness and underdiagnosis remain major barriers to the growth of the infectious disease treatment market.- Opportunities: Self-testing kits are rapidly gaining traction in the field of infectious diseases, offering individuals convenient, private, and timely diagnostic options. Market leaders include: ABBOTT ABBVIE INC. CSL DANAHER CORP. F. HOFFMANN-LA ROCHE LTD. GILEAD SCIENCES INC. GSK PLC JOHNSON & JOHNSON MERCK & CO. INC. MOLBIO DIAGNOSTICS LTD. ORASURE TECHNOLOGIES INC. PFIZER INC. SANOFI SERUM INSTITUTE OF INDIA PVT. LTD. SIEMENS HEALTHINEERS Related reports: The Global Influenza Market: This report provides a comprehensive review of the global influenza market, offering qualitative and quantitative insights. It explores the historical context of flu pandemics, current disease burden, and vaccine coverage across key regions. The market is segmented into vaccines (inactivated and live-attenuated), therapeutics, and diagnostics (rapid and conventional tests), with detailed analysis of each category. It also highlights leading products, clinical trials, new approvals, and emerging technologies. Regional demographics and growth prospects in North America, Europe, and Asia-Pacific are examined, along with strategic profiles of major companies operating in the influenza sector. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
